IBB:NSD-iShares Biotechnology ETF (USD)

ETF | Health |

Last Closing

USD 145.06

Change

+2.21 (+1.55)%

Market Cap

USD 7.19B

Volume

0.94M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
PPH VanEck Pharmaceutical ETF

-0.07 (-0.08%)

USD 0.67B
BBH VanEck Biotech ETF

+2.80 (+1.64%)

USD 0.43B
PSCH Invesco S&P SmallCap Health Ca..

+0.71 (+1.60%)

USD 0.18B
PTH Invesco DWA Healthcare Momentu..

+0.45 (+0.99%)

USD 0.14B
GNOM Global X Genomics & Biotechnol..

+0.07 (+0.66%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti..

+0.24 (+0.84%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET..

+0.20 (+1.34%)

USD 0.01B

ETFs Containing IBB

IBB3:LSE 300.12 % 0.00 %

N/A

N/A
HAC.A:CA 0.00 % 3.14 %

N/A

N/A
HAC:CA Global X Seasonal Rotatio.. 0.00 % 1.27 %

-0.13 (0%)

CAD 0.22B
IBBS:LSE -299.94 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.41% 38% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.41% 38% F 10% F
Trailing 12 Months  
Capital Gain -59.81% 25% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.81% 25% F 11% F
Trailing 5 Years  
Capital Gain -55.37% 25% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.37% 25% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 1.65% 38% F 43% F
Dividend Return 1.88% 38% F 39% F
Total Return 0.23% 50% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 21.26% 63% D 76% C+
Risk Adjusted Return 8.84% 50% F 41% F
Market Capitalization 7.19B 100% F 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.